Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib versus adalimumab induction therapy for refractory moderate-to-severe active intestinal Behçet's disease
ChiCTR2600133769Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastrointestinal Behçet's disease (GI-BD) comparing Upadacitinib group with Adalimumab group (2 arms). Primary endpoint: Clinical response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
upadacitinibadalimumab
03
Conditions
gastrointestinal Behçet's disease (GI-BD)
Beyond the preview
Go deeper on ChiCTR2600133769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133769.